Novo Still Has Work to Do to Build Investor Confidence, CEO Says

Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopoly on all the good ideas," Doustdar tells Bloomberg Television. "When there is a…

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.